Status:
COMPLETED
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
Lead Sponsor:
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Conditions:
Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is an open-label, dose escalation study of intravenous ARQ 621 administered to patients with late-stage solid tumors or hematologic malignancies.
Detailed Description
The study is designed to explore the safety, tolerability and pharmacokinetics of ARQ 621 and define a recommended phase 2 (RP2D)dose of ARQ 621.Treatment will be initiated at a dose level of 10 mg/m\...
Eligibility Criteria
Inclusion
- Signed written informed consent must be obtained and documented according to International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP), the local regulatory requirements, and permission to use private health information in accordance with the Health Insurance Portability and Accountability Act (HIPPA) prior to study-specific screening procedures
- A histologically or cytologically confirmed metastatic solid tumor or refractory/relapsed hematologic malignancy
- Have a life expectancy of at least 12 weeks
- ≥18 years of age
- Measurable disease as defined by:
- Solid Tumors: Response Evaluation Criteria in Solid Tumors
- Multiple Myeloma (MM): International Uniform Response Criteria, at least one of the following:
- Monoclonal protein in the plasma of ≥0.5 g/dL
- Monoclonal protein in the urine of ≥0.2 g/24 hr urine collection
- Serum immunoglobulin free light chain (FLC) ≥100 mg/L (10 mg/dL) and abnormal serum immunoglobulin kappa to lambda FLC ratio
- Malignant Lymphoma (ML): International Working Group Response Criteria
- At least one site of disease ≥2 cm in longest diameter (a lesion ≥1 cm can be considered if PET positive)
- Chronic Lymphocytic Leukemia (CLL): NCI Working Group Guidelines
- Lymphocytosis (5 x 10\^9 /L) with B-cell marker (CD19, CD20,CD23) + CD5
- High-risk characteristics (hemoglobin \<10g/dL OR platelets \<100 x 10\^9 /L)
- Acute Myelogenous Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL): only patients with bone marrow or peripheral blast count of ≥20%
- Acute Promyelocytic Leukemia (APML): patients must be refractory to all-trans retinoic acid (ATRA) and arsenic trioxide
- Chronic Myelogenous Leukemia (CML): patients in blast crisis (bone marrow or peripheral blast count ≥20%) may be included if refractory to prior therapy and to any therapy the investigators deems of higher priority (for example, BCR-ABL inhibitors such as imatinib mesylate \[Gleevec\], nilotinib \[Tasigna\], or dasatinib \[Sprycel\])
- ECOG performance status ≤2
- Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last ARQ 621 dose
- Females of childbearing potential must have a negative serum pregnancy test
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 × upper limit of normal (ULN) or ≤5.0 × ULN with metastatic liver disease
- Hemoglobin (Hgb) ≥10 g/dL (except in cases considered related to hematologic malignancy)
- Total bilirubin ≤1.5 × ULN
- Creatinine ≤1.5 x ULN (≤2.0 x ULN in cases considered related to multiple myeloma)
- Absolute neutrophil count ≥1.5 x 10\^9/L (except in cases considered related to hematologic malignancy)
- Platelets ≥100 x 10\^9/L (except in cases considered related to hematologic malignancy)
- Patients with hematologic malignancies who have progressed following at least two prior treatment regimens
Exclusion
- Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within four weeks of the first dose
- In cases of hematologic malignancies, 4-week recovery from prior anticancer treatment is not required, however the patient must recover from prior treatment-related non-hematological toxicities to grade 2 or less
- When required for supportive care corticosteroids or hydroxyurea may be used
- Surgery within four weeks prior to the first dose
- Known untreated brain metastases or leptomeningeal disease
- Patients with solid tumors who were treated for brain metastases and who have shown stable disease for at least 8 weeks prior to enrollment will be allowed
- Pregnant or breastfeeding
- Uncontrolled concurrent illness including, but not limited to ongoing or active symptomatic infection requiring systemic therapy, clinically significant non-healing or healing wounds, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements
- Patients having a history of Thrombotic thrombocytopenic purpura (TTP) or Hemolytic-uremic syndrome (HUS) or HUS spectrum will be excluded from the study
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00825487
Start Date
August 1 2009
End Date
September 1 2011
Last Update
October 19 2011
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Translational Genomics Institute
Phoenix, Arizona, United States, 85004
2
Premiere Oncology
Santa Monica, California, United States, 90404
3
Boston, Massachusetts, United States, 02111
4
Nevada Cancer Institute
Las Vegas, Nevada, United States, 89135